Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026, indicating non-compliance with the minimum bid price requirement under Listing Rule 5550(a)(2). The company's American Depositary Shares (ADSs) traded below $1.00 per share for 30 consecutive business days, triggering the deficiency notice. However, the notification does not immediately affect the listing or trading of Scinai's ADSs on the Nasdaq Capital Market.
According to the press release, Scinai has been granted a 180-day compliance period, which extends through September 8, 2026. During this period, the company can regain compliance if its closing bid price meets or exceeds $1.00 per share for at least 10 consecutive business days. If Scinai achieves this within the compliance period, Nasdaq will confirm compliance and the matter will be resolved.
This development is significant for Scinai as it navigates the challenges of maintaining its Nasdaq listing, which is crucial for investor visibility and access to capital markets. Non-compliance with the minimum bid price rule is a common issue among small-cap biotech companies, often reflecting broader market sentiment or company-specific challenges. For Scinai, which is focused on developing innovative immunology therapies, the ability to regain compliance within the given timeframe will be closely watched by investors.
Scinai Immunotherapeutics is a biopharmaceutical company advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO) that provides development and manufacturing services to biotechnology and pharmaceutical firms. The company's dual focus on proprietary drug development and CDMO services may offer some resilience, but the stock's performance will be key to meeting Nasdaq's requirements.
Investors can find the latest news and updates regarding SCNI in the company's newsroom at https://ibn.fm/SCNI. The full press release is available at https://ibn.fm/faOR5.
As the 180-day compliance period unfolds, stakeholders will be monitoring Scinai's stock performance and any strategic moves the company may undertake to bolster its share price. The outcome will determine whether Scinai can continue trading on the Nasdaq Capital Market without interruption.
